Calretinin as a blood-based biomarker for mesothelioma

Calretinin as a blood-based biomarker for mesothelioma

Abstract Background Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With a latency period up to 50 years the incidence of MM is still increasing, even in countries that banned asbestos. Secondary prevention has been established to provide persons at ris...

Full description

Bibliographic Details
Main Authors: Georg Johnen, Katarzyna Gawrych, Irina Raiko, Swaantje Casjens, Beate Pesch, Daniel G. Weber, Dirk Taeger, Martin Lehnert, Jens Kollmeier, Torsten Bauer, Arthur W. Musk, Bruce W. S. Robinson, Thomas Brüning, Jenette Creaney
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Mesothelioma
Sarcomatoid
Epithelioid
Biphasic
Asbestos
Biomarker panel
Online Access:http://link.springer.com/article/10.1186/s12885-017-3375-5

Internet

http://link.springer.com/article/10.1186/s12885-017-3375-5

Similar Items